The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kashtanova E.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Polonskaya Ya.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Shcherbakova L.V.

Research Institute of Internal and Preventive Medicine — Branch of Federal Research Center Institute of Cytology and Genetics

Stakhneva E.M.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Shramko V.S.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Sadovski E.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Denisova D.V.

Research Institute of Internal and Preventive Medicine — Branch of Federal Research Center Institute of Cytology and Genetics

Ragino Yu.I.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences

Prevalence of therapeutic diseases depending on cytokines/chemokines levels in people under 45 years

Authors:

Kashtanova E.V., Polonskaya Ya.V., Shcherbakova L.V., Stakhneva E.M., Shramko V.S., Sadovski E.V., Denisova D.V., Ragino Yu.I.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2024;27(7): 46‑52

Read: 909 times


To cite this article:

Kashtanova EV, Polonskaya YaV, Shcherbakova LV, et al. . Prevalence of therapeutic diseases depending on cytokines/chemokines levels in people under 45 years. Russian Journal of Preventive Medicine. 2024;27(7):46‑52. (In Russ.)
https://doi.org/10.17116/profmed20242707146

Recommended articles:
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
Biomarkers of athe­rothrombotic and cardioembolic subtypes of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):20-26

References:

  1. Bochkareva LA, Nedosugova LV, Petunina NA, et al. Some mechanisms of inflammation development in type 2 diabetes mellitus. Saharnyj diabet. 2021;24(4):334-341. (In Russ.). https://doi.org/10.14341/DM12746
  2. Zhmurov DV, Zhmurov VA, Petrov IM, et al. Indicators of systemic inflammation and state of the cardiovascular system in patients with chronic kidney disease. Terapija. 2023;9(3):15-20. (In Russ.). https://doi.org/10.18565/therapy.2023.3.15-20
  3. Kazakova M, Vysotskaya K, Mitkovskaya N. The role of inflammation in the pathogenesis of atherosclerosis. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski. 2022;6(2):1707-1713. (In Russ.). https://doi.org/10.51922/2616-633X.2022.6.2.1707
  4. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1): 111-188.  https://doi.org/10.1093/eurheartj/ehz455
  5. Rydén L, Grant PJ, Anker SD, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035-3087. https://doi.org/10.1093/eurheartj/eht108
  6. Arterial hypertension in adults. Clinical guidelines 2020. Rossijskij kardiologicheskij zhurnal. 2020;25(3):3786. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
  7. Kokosov AN. Chronic obstructive bronchitis. Klinicheskaya meditsina. 1999; 1:11-16. (In Russ.).
  8. Gupta J, Mitra N, Kanetsky PA, et al. CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clinical Journal of the American Society of Nephrology: CJASN. 2012;7(12):1938-1946. https://doi.org/10.2215/CJN.03500412
  9. Romanova Y, Laikov A, Markelova M, et al. Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease. Biomolecules. 2020; 10(2):257.  https://doi.org/10.3390/biom10020257
  10. Webster AC, Nagler EV, Morton R, Masson P. Chronic Kidney Disease. Lancet (London, England). 2017;389:1238-1252. https://doi.org/10.1016/S0140-6736(16)32064-5
  11. Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nature Reviews. Nephrology. 2017;13:344-358.  https://doi.org/10.1038/nrneph.2017.52
  12. del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomakers, and why it matters. Brain, Behavior, and Immunity. 2018;70:61-75.  https://doi.org/10.1016/j.bbi.2018.02.013
  13. Murkamilov IT. The bi-directional effect of markers of inflammation and a decrease in glomerular filtration rate in chronic kidney disease. Klinicheskaia laboratornaia diagnostika. 2022;67(1):37-42. (In Russ.). https://doi.org/10.51620/0869-2084-2022-67-1-37-42
  14. Lainampetch J, Panprathip P, Phosat C, et al. Association of Tumor Necrosis Factor Alpha, Interleukin 6, and C-Reactive Protein with the Risk of Developing Type 2 Diabetes: A Retrospective Cohort Study of Rural Thais. Journal of Diabetes Research. 2019;051929. https://doi.org/10.1155/2019/9051929
  15. Clarke R, Valdes-Marquez E, Hill M, et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open Heart. 2018;5(1):000807. https://doi.org/10.1136/openhrt-2018-000807
  16. Jayedi A, Rahimi K, Bautista LE, et al. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. Heart (British Cardiac Society). 2019;105(9):686-692.  https://doi.org/10.1136/heartjnl-2018-314216
  17. Gökaslan S, Özer Gökaslan Ç, Demirel E, Çelik S. Role of aortic stiffness and inflammation in the etiology of young-onset hypertension. Turkish Journal of Medical Sciences. 2019;49(6):1748-1753. https://doi.org/10.3906/sag-1908-137
  18. Chamarthi B, Williams GH, Ricchiuti V, et al. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. American Journal of Hypertension. 2011;24(10): 1143-1148. https://doi.org/10.1038/ajh.2011.113
  19. Stumpf C, Raaz D, Klinghammer L, et al. Platelet CD40 contributes to enhanced monocyte chemoattractant protein 1 levels in patients with resistant hypertension. European Journal of Clinical Investigation. 2016;46(6):564-571.  https://doi.org/10.1111/eci.12635

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.